Syncona Limited
Update on management of strategic capital pool
12 March 2019
Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life science, today announces an update on the management of its capital pool.
Over the last two years, Syncona has evolved the investment parameters of its strategic capital pool to focus on liquidity and capital preservation in order to support Syncona's strategy and key goal of founding, building and funding global leaders in life science. To support this strategy, we will be simplifying the management of Syncona's capital pool. Accordingly, over the next three to six months, Syncona will be significantly reducing its fund investments and further increasing its weighting to cash, cash equivalents and fixed income products with higher liquidity and lower volatility.
Martin Murphy, CEO, Syncona Investment Management Limited, said: "This is a natural next step for the management of our capital pool. Our life science portfolio has generated significant value to date, with the offer for Nightstar demonstrating our ability to deliver strong returns. Successful life science companies scale rapidly, and our existing portfolio is now at the stage where our strategic capital pool ideally positions Syncona to capitalise on the commercial opportunities ahead of us.
I would like to thank our Head of Fund Investments, Arabella Cecil, for her great contribution to Syncona, successfully managing the fund investments as part of our strategic pool of capital to enable us to fund our vision to create global leaders in life science."
[ENDS]
Enquiries
Syncona Ltd
Annabel Clay
Tel: +44 (0) 20 7611 2031
Tulchan Communications
Martin Robinson
Lisa Jarrett-Kerr
Tel: +44 (0) 207 353 4200
Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com
About Syncona:
Syncona is a leading FTSE250 healthcare company focused on founding, building and funding global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.
We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.
We take a long-term view, underpinned by a deep pool of capital, and are established leaders in gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.
